Skeletal muscle susceptibility to clofibrate induction of lesions in rats.
Morphological changes induced by clofibrate in type-1 predominant soleus, type-2 predominant tensor fasciae latae, and type-1 and -2 mixed biceps femoris muscles and diaphragm in rats were investigated. Administration of the agent at 500 or 750 mg/kg/day by oral gavage for 14 or 28 days caused lesions in the soleus muscle and diaphragm, bur no changes in the tensor fasciae latae and biceps femoris muscles. In soleus muscle, vacuolation of muscle fibers was observed in all animals treated with clofibrate, and degeneration of muscle fibers and infiltration of leukocytes were noted at 750 mg/kg/day. In diaphragm, vacuolation of muscle fibers was also observed in all animals treated with clofibrate, and these lesions were located in type-1 skeletal muscles densely stained with NADH-TR. The vacuoles seen in soleus muscle and diaphragm were positive for oil red O staining. In addition, increase of lipid droplets and mitochondrial hypertrophy was seen in soleus muscle, ultrastructurally. These data suggest that sensitivity to clofibrate-induced muscle toxicity differs among muscles, with type-1 fibers being susceptible.
Okada
Miyoko
M
Toxicology Laboratory, Mitsubishi Pharma Corporation, Kisarazu, Chiba, Japan. Okada.Miyoko@mg.m-pharma.co.jp
Inoue
Yoshimi
Y
Ube
Masayuki
M
Sano
Fumiko
F
Ikeda
Itsuko
I
Sugimoto
Jiro
J
Takagi
Shiro
S
D000818:Animals; D002994:Clofibrate / Q000633:toxicity*; D003964:Diaphragm / Q000473:pathology; D005260:Female; D000960:Hypolipidemic Agents / Q000633:toxicity*; D008854:Microscopy, Electron; D008931:Mitochondria, Muscle / Q000187:drug effects / Q000473:pathology / Q000648:ultrastructure; D018482:Muscle, Skeletal / Q000473:pathology* / Q000648:ultrastructure; D009135:Muscular Diseases / Q000139:chemically induced* / Q000473:pathology*; D051381:Rats; D017207:Rats, Sprague-Dawley
D000960:Hypolipidemic Agents; D002994:Clofibrate